ArticleDisease markers2017
Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
Article in Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- A different perspective on the cancer stem cell theory.Medical oncology (Northwood, London, England) · 2026Review
- Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models.International journal of molecular sciences · 2025Article
- Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- A Novel Anti-CD44 Variant 9 Monoclonal Antibody CCurrent issues in molecular biology · 2023Article
- Genome-Wide Analysis of lncRNA-mRNA Co-Expression Networks in CD133+/CD44+ Stem-like PDAC Cells.Cancers · 2023Article
- The dual role of p63 in cancer.Frontiers in oncology · 2023Review
- CD44Journal of the Egyptian National Cancer Institute · 2022Article
- Current Pathology Model of Pancreatic Cancer.Cancers · 2022Review
- Effects of tRNA-derived fragments and microRNAs regulatory network on pancreatic acinar intracellular trypsinogen activation.Bioengineered · 2022Article
- CD44: A Multifunctional Mediator of Cancer Progression.Biomolecules · 2021Review
- The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance.Cancer metastasis reviews · 2021Review
- Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence.Cancers · 2021Article
- Tumour stem cell markers CD133 and CD44 are useful prognostic factors after surgical resection of pancreatic neuroendocrine tumours.Oncology letters · 2020Article
- Targeting Liver Cancer Stem Cells: An Alternative Therapeutic Approach for Liver Cancer.Cancers · 2020Review
- Identification of Acute Pancreatitis-Related Genes and Pathways by Integrated Bioinformatics Analysis.Digestive diseases and sciences · 2020Article
- Promoter-Level Transcriptome Identifies Stemness Associated With Relatively High Proliferation in Pancreatic Cancer Cells.Frontiers in oncology · 2020Article
- Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.Molecular biology reports · 2019Review
- The Role of Notch Signaling and Leptin-Notch Crosstalk in Pancreatic Cancer.Medicines (Basel, Switzerland) · 2018Review
- Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour.Journal of Cancer · 2018Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSC) play an important role in pancreatic carcinogenesis and prognosis. The study aimed at examining the expression of CD24, CD44, and CD133 in human PDAC and CP in order to evaluate its clinicopathological correlations and the clinical significance. Surgical specimens from 23 patients with PDAC and 15 patients with chronic pancreatitis after pancreatic resection were stained with CD24, CD44, and CD133 antibodies. The intensity of staining was scored from 0 (negative) to 3 (strongly positive).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.